Cataba­sis shares are shred­ded af­ter lead drug flops in PhII Duchenne MD study

Cataba­sis’ lead drug just flopped in a Phase II study for Duchenne mus­cu­lar dy­s­tro­phy, evis­cer­at­ing its stock af­ter yet an­oth­er clin­i­cal set­back rais­es ques­tions about …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER